伊瓦布拉丁在败血症休克:一个叙事审查
Marco Pasetto1,2, Lorenzo Antonino Calabrò1, Filippo Annoni1
1Department of Intensive Care, Hôpital Erasme, Université Libre de Bruxelles, 1070 Brussels, Belgium.
Journal of clinical medicine
|April 27, 2024
概括
在败血性休克中持续性心力衰竭表明自主功能障碍,并预测不良结果. 伊瓦布拉丁是一种心率降低药物,可以通过选择性地降低心率而改善血液动力学,而不会影响收缩能力.
科学领域:
- 关键护理医学 关键护理医学
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 在败血性休克中,补偿性心动减速可以在治疗中持续存在,这表明自主功能功能障碍.
- 持续高心率是危急疾病中不良结果的独立预测因素.
- 心率升高会对心脏功能产生负面影响,增加心肌的氧气需求,损害心室填充和放松.
研究的目的:
- 审查使用伊瓦布拉丁在败血性休克患者的机制和证据.
- 探索伊瓦布拉丁在这种人群中改善血液动力学功能的潜力.
主要方法:
- 关于心率,自主功能障碍和伊瓦布拉丁在败血症休克中的研究的文献综述.
- 对伊瓦布拉丁对阴耳节点心脏起器电流 (If) 的药理作用的评估.
主要成果:
- 伊瓦布拉丁通过抑制If电流而选择性地降低心率,而不会影响心脏收缩性.
- 这种选择性慢性效应可能会改善心室动脉合,并降低心脏填充压力.
- 潜在的好处包括改善心肌氧氧气供需平衡,降低心律失常风险.
结论:
- 伊瓦布拉丁的独特机制提供了一个潜在的治疗策略,用于管理性休克时的持续性心力衰竭.
- 需要进一步的临床试验来证实其有效性和安全性,以改善心脏功能障碍的败血症休克患者的治疗结果.
相关概念视频
Blood Pressure Imbalances and Circulatory Shock
772
Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
772
Heart Failure Drugs: Inotropic Agents
574
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
574
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
741
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
741
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Pharmacovigilance
829
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
829


